Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?

Susanne Elisabeth Hosbond, Axel Cosmus Pyndt Diederichsen, Lotte Saaby, Lars Melholt Rasmussen, Jess Lambrechtsen, Henrik Munkholm, Niels Peter Rønnow Sand, Oke Gerke, Tina Svenstrup Poulsen, Hans Mickley

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP).

METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values.

RESULTS: OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95% CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2% (95% CI: 49.2-63.0%) and a specificity of 62.9% (95% CI: 57.3-68.2%).

CONCLUSION: OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.

Original languageEnglish
JournalAtherosclerosis
Volume236
Issue number2
Pages (from-to)230-236
ISSN0021-9150
DOIs
Publication statusPublished - 2014

Fingerprint

Osteoprotegerin
Coronary Artery Disease
ROC Curve
Stable Angina
Coronary Angiography
Area Under Curve
Pathologic Constriction

Cite this

@article{169d54ef42ed4213bc166c182fe030a5,
title = "Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?",
abstract = "PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP).METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values.RESULTS: OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95{\%} CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2{\%} (95{\%} CI: 49.2-63.0{\%}) and a specificity of 62.9{\%} (95{\%} CI: 57.3-68.2{\%}).CONCLUSION: OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.",
author = "Hosbond, {Susanne Elisabeth} and Diederichsen, {Axel Cosmus Pyndt} and Lotte Saaby and Rasmussen, {Lars Melholt} and Jess Lambrechtsen and Henrik Munkholm and Sand, {Niels Peter R{\o}nnow} and Oke Gerke and Poulsen, {Tina Svenstrup} and Hans Mickley",
note = "Copyright {\circledC} 2014 Elsevier Ireland Ltd. All rights reserved.",
year = "2014",
doi = "10.1016/j.atherosclerosis.2014.07.013",
language = "English",
volume = "236",
pages = "230--236",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier",
number = "2",

}

Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? / Hosbond, Susanne Elisabeth; Diederichsen, Axel Cosmus Pyndt; Saaby, Lotte; Rasmussen, Lars Melholt; Lambrechtsen, Jess; Munkholm, Henrik; Sand, Niels Peter Rønnow; Gerke, Oke; Poulsen, Tina Svenstrup; Mickley, Hans.

In: Atherosclerosis, Vol. 236, No. 2, 2014, p. 230-236.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?

AU - Hosbond, Susanne Elisabeth

AU - Diederichsen, Axel Cosmus Pyndt

AU - Saaby, Lotte

AU - Rasmussen, Lars Melholt

AU - Lambrechtsen, Jess

AU - Munkholm, Henrik

AU - Sand, Niels Peter Rønnow

AU - Gerke, Oke

AU - Poulsen, Tina Svenstrup

AU - Mickley, Hans

N1 - Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

PY - 2014

Y1 - 2014

N2 - PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP).METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values.RESULTS: OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95% CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2% (95% CI: 49.2-63.0%) and a specificity of 62.9% (95% CI: 57.3-68.2%).CONCLUSION: OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.

AB - PURPOSE: The biomarker Osteoprotegerin (OPG) is associated with coronary artery disease (CAD). The main purpose of this study was to evaluate the diagnostic value of OPG in healthy subjects and in patients with suspected angina pectoris (AP).METHODS: A total of 1805 persons were enrolled: 1152 healthy subjects and 493 patients with suspected AP. For comparison 160 patients with acute myocardial infarction (MI) were included. To uncover subclinical coronary atherosclerosis, a non-contrast cardiac-CT scan was performed in healthy subjects; while in patients with suspected AP a contrast coronary angiography was used to detect significant stenosis. OPG concentrations were analyzed and compared between groups. ROC-analyses were performed to estimate OPG cut-off values.RESULTS: OPG concentrations increased according to disease severity with the highest levels found in patients with acute MI. No significant difference (p = 0.97) in OPG concentrations was observed between subgroups of healthy subjects according to severity of coronary calcifications. A significant difference (p < 0.0001) in OPG concentrations was found between subgroups of patients with suspected stable AP according to severity of CAD. ROC-analysis showed an AUC of 0.62 (95% CI: 0.57-0.67). The optimal cut-off value of OPG (<2.29 ng/mL) had a sensitivity of 56.2% (95% CI: 49.2-63.0%) and a specificity of 62.9% (95% CI: 57.3-68.2%).CONCLUSION: OPG cannot be used to differentiate between healthy subjects with low versus high levels of coronary calcifications. In patients with suspected AP a single OPG measurement is of limited use in the diagnosis of CAD.

U2 - 10.1016/j.atherosclerosis.2014.07.013

DO - 10.1016/j.atherosclerosis.2014.07.013

M3 - Journal article

C2 - 25104079

VL - 236

SP - 230

EP - 236

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -